Sernova Biotherapeutics

Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b

Several companies are developing islet cell-based therapies for type 1 diabetes, and all face the same two problems: avoiding the host’s immune response to foreign tissue, and manufacturing at scale.

Sernova Corp is working to develop a functional cure for type 1 diabetes that could free patients from a lifetime of insulin injections, but despite some early encouraging clinical data and a potenti

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning